{"schema_version":"secwatch.filing_event.v1","accession":"0001387131-23-008595","form_type":"8-K","ticker":null,"cik":"0000887247","company_name":"DMK PHARMACEUTICALS Corp","filed_at":"2023-07-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:36.887986+00:00","generated_at":"2026-06-13T04:41:20.277118+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"CFO David Benedicto resigns; President/COO Marguglio named interim CFO","bullets":["David C. Benedicto resigned as CFO and principal accounting officer, effective July 21, 2023.","Resignation not due to any disagreement with the company or auditors on financial matters.","David J. Marguglio, President and COO, appointed interim CFO while a permanent replacement is sought.","Marguglio has been with Adamis since 2009 and previously served as CEO until the DMK merger in May 2023.","Company will commence a search for a new CFO; no formal arrangement or understanding with Mr. Marguglio."],"urls":{"canonical":"https://secwatch.observer/filing/0001387131-23-008595","json":"https://secwatch.observer/filing/0001387131-23-008595.json","markdown":"https://secwatch.observer/filing/0001387131-23-008595.md","text":"https://secwatch.observer/filing/0001387131-23-008595.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/887247/000138713123008595/0001387131-23-008595-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/887247/000138713123008595/admp-8k_071823.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T04:41:20.277118+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b0b6ce7a4d","claim":"David C. Benedicto resigned as chief financial officer and principal accounting officer at DMK PHARMACEUTICALS Corp.","evidence_excerpt":"On July 18, 2023, David C. Benedicto, the chief financial officer and principal accounting officer of Adamis Pharmaceuticals Corporation (the “Company”), notified the Company that he was tendering his resignation from the Company effective July 21, 2023.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/887247/000138713123008595/0001387131-23-008595-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"chief financial officer and principal accounting officer"}],"fact_type":"executive_change"},{"claim_id":"d7cb221a2c","claim":"David J. Marguglio was appointed as interim chief financial officer at DMK PHARMACEUTICALS Corp.","evidence_excerpt":"In the interim, David J. Marguglio, the Company’s President and Chief Operating Officer, will assume the duties of chief financial officer of the Company on an interim basis until the Company appoints a successor, and the board of directors of the Company has approved that appointment.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/887247/000138713123008595/0001387131-23-008595-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"interim chief financial officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}